Explaining the stable coexistence of drug-resistant and -susceptible pathogens: the Resistance Acquisition Purifying Selection model

Pleuni S Pennings

San Francisco State University

1600 Holloway Ave, San Francisco, CA 94132

pennings@sfsu.edu

Abstract

Drug resistance is a problem in many pathogens. While overall, levels of resistance have risen in recent decades, there are many examples where after an initial rise, levels of resistance have stabilized. The stable coexistence of resistance and susceptibility has proven hard to explain – in most evolutionary models, either resistance or susceptibility ultimately "wins" and takes over the population. Here, we show that a simple stochastic model, mathematically akin to mutation-selection balance theory, can explain several key observations about drug resistance: (1) the stable coexistence of resistant and susceptible strains (2) at levels that depend on population-level drug usage and (3) with resistance often due to many different strains (resistance is present on many different genetic backgrounds). The model works for resistance due to both mutations or horizontal gene transfer (HGT). It predicts that new resistant strains should continuously appear (through mutation or HGT and positive selection within treated hosts) and disappear (due to a fitness cost of resistance). The result is that while resistance is stable, *which* strains carry resistance is constantly changing. We used data from a longitudinal genomic study on *E. coli* in Norway to test this prediction for resistance to five different drugs and found that, consistent with the model, most resistant strains indeed disappear quickly after they appear in the dataset. Having a model that explains the dynamics of drug resistance will allow us to plan science-backed interventions to reduce the burden of drug resistance.

Keywords: drug resistance; antibiotic resistance; coexistence; mutation-selection balance; HIV; E. coli.

Graphical abstract

Introduction

Drug resistance is common in viruses (HIV), bacteria (*S. aureus*, *E. coli, M. tuberculosis)*, parasites (*P. falciparum*) and fungi (*Candida* species), making it a major public health threat (Murray et al. 2022). What can we do to prevent the rise of drug-resistant strains? Or to revert the trend if the level of resistance is already high? To plan successful science-backed interventions, we must understand what determines the level of drug resistance in a given pathogen. Therefore, a need exists for better models to explain current resistance levels, predict how resistance rates will change over time and identify which interventions would most reduce the burden of resistance. Here, we present a simple model that does all of these things.

Any model that might be used to predict drug resistance levels for different pathogens must be able to explain several observations that are currently not well explained (Davies et al. 2019; Krieger et al. 2020; Colijn et al. 2009). First, while overall drug resistance has increased over the years, in many cases, an initial increase in resistance is followed by stable coexistence between drug-resistant and drug-sensitive strains. For an example, see **Figure 1A** on quinolone resistance in *E. coli* in Europe. Other examples of stable coexistence of resistant and susceptible strains can be found in *S. pneumoniae* (Colijn et al. 2009; Krieger et al. 2020), *S. aureus* (Diekema et al. 2019) and HIV (Rhee et al. 2019; Rocheleau et al. 2018)). Second, a positive linear relationship has been observed between treatment intensity at the population level and drug resistance levels (Goossens et al. 2005) (**Figure 1B).** And third, many different resistant strains (i.e., resistance on different genetic backgrounds) often segregate at the same time in a pathogen population (Nübel et al. 2008; Rhee et al. 2019) (see **Figure 1C** for an example of resistance to the quinolone drug

ciprofloxacin in *E. coli* in the UK; resistance appears repeatedly on the phylogenetic tree (van Nouhuijs et
al. 2022; Kallonen et al. 2017)).

The second observation feels intuitive to most of us: If we use more drugs, we get more drug
resistance. But the first observation, of stable coexistence, is puzzling: if there is selection *for* drug
resistance, why doesn't the level of resistance keep increasing until it reaches 100%? The third observation,
of resistance in many strains or genetic backgrounds, can be seen in many phylogenetic trees in articles
about drug resistance, but usually does not receive a lot of attention. For example, in a large study of HIV
isolates in Northern California, Rhee and colleagues found 82 phylogenetic clusters with one or more drug-
resistance mutations (Rhee et al. 2019). In an *E. coli* dataset from the UK, 31 independent phylogenetic
clusters with ciprofloxacin-resistant strains were found (van Nouhuijs et al. 2022), and Casali and
colleagues found 106 independent phylogenetic clusters with pyrazinamide resistance in *M. tuberculosis*
(Casali et al. 2014). These results show that resistance has evolved *de novo* or been acquired through
horizontal gene transfer (HGT) many times (Nubel et al. 2008; Shin, Choi, and Ko 2012).

Several different explanations have been put forward to explain the coexistence of resistance and
susceptibility and the positive relationship between treatment and resistance levels (Colijn et al. 2009;
Krieger et al. 2020). These explanations have usually focused on mechanisms that require population
structure or coinfection to create stabilizing selection (Colijn et al. 2009; Krieger et al. 2020; Cobey et al.
2017; Kouyos, Klein, and Grenfell 2013; Blanquart et al. 2018). We propose a simpler model akin to
mutation-selection balance. Our model requires few assumptions, which means it could be applicable to a
large variety of pathogens, and few parameters, which makes it easy to use.

We call our model the "resistance acquisition and purifying selection" (RAPS) model and will
show that it can explain all three key observations about drug resistance listed previously. We will also
describe which observations cannot directly be explained by the RAPS model. Note that when resistance is
due to HGT, we don't aim to explain why genetic elements that confer drug resistance exist or how they
evolved, but rather why they are carried by a stable frequency of strains in pathogen populations.

74
Figure 1. Three key observations about drug resistance, illustrated with data on resistance to quinolones in *E.*
coli. a. *Observation 1. Typically, an initial increase in resistance is followed by stable coexistence between drug-*
resistant and drug-sensitive strains. Each line depicts the fraction of E. coli strains resistant to quinolones in a country
over two decades in the 10 most populous countries (formerly) in the European Union (EU). ***b.*** *Observation 2.*
Treatment intensity at the country level is correlated with drug resistance levels. A strong positive correlation exists
between quinolone usage and quinolone resistance levels in 20 countries in the EU. Publicly available data from the
[Surveillance Atlas of Infectious Diseases](#) were used to create Figures 1a and 1b (ECDC 2023; 2018). ***c.*** *Observation*
3. Many different resistant strains often segregate at the same time. Quinolone (specifically ciprofloxacin) resistance
in bacteremia patients in the UK is due to many different origins of resistance (here only phylogroup D and F are
shown). Data from (Kallonen et al. 2017), figure reproduced from (van Nouhuijs et al. 2022).

The resistance acquisition – purifying selection (RAPS) model

Here we show that the RAPS model based on classic mutation-selection balance can explain the three
striking observations of drug resistance at the population level: (1) a stable coexistence of resistance and
susceptibility, (2) a positive relationship between drug usage and resistance levels, and (3) the simultaneous
existence of many drug-resistant strains. Note that our goal here is not to determine whether the RAPS

model can better explain the data than the models proposed by others. Instead, we provide a proof of concept
to show that the model can, in principle, lead to the main observations and should be considered as a
possibility. The RAPS model works for resistance acquisition due to *de novo* mutation or HGT.
The RAPS model is based on the classic mutation-selection balance model, because this model has
already been used to explain a stable level of deleterious mutations and the existence of multiple alleles that
carry a deleterious mutation (Wakeley 2008; Hartl and Campbell 1982). Mutation-selection balance is a
well-understood dynamic equilibrium, and we can borrow mathematical results from that theory directly
here (Baum et al. 2017; Hartl and Clark 2006).
While mutation-selection balance has been considered by a few authors (Boni et al. 2006;
Rodrigues, Gomes, and Rebelo 2007; Davies et al. 2021; Colijn et al. 2009), it has generally not received
much attention as a potential explanation for drug resistance patterns. We see three main reasons for this
omission: First, it is erroneously believed that mutation-selection balance can only lead to resistance
frequencies close to 0% or close to 100% (Colijn et al. 2009) whereas observed drug resistance frequencies
are often much higher. Second, in the basic form, the model only considers negative selection (*against*
mutations) and not positive selection (*for* mutations), whereas in the case of drug resistance, we know that
positive selection plays an important role too. Third, a lot of focus in drug resistance research has been on
well-established resistant strains and new acquisition of resistance is considered too uncommon (Davies et
al. 2021).
In the basic mutation-selection balance model, mutation creates deleterious alleles at probability μ
per individual per generation and these alleles reduce the fitness of the individual carrying them by selection
coefficient *s* per generation, see Table 1. Standard population genetic theory then predicts that the
deleterious allele frequency is μ/s (Barton et al. 2007).
To apply mutation-selection equilibrium theory to the problem of drug resistance, we make several
adjustments. First, as others have done, we treat the population of a pathogen in a host as an individual,
which means that a host can either be infected by a resistant pathogen or a susceptible pathogen and when
evolution happens in a host it is instantaneous (Gordo et al. 2009). Hosts can be infected (I), susceptible to
infection (S) and recovered (R). Time is measured in units of duration of infection, so that R0 is the expected
number of new infections (i.e., newly colonized hosts) in a situation where all hosts are susceptible to
infection (Gordo et al. 2009) (alternatively, time could be measured per month or year, as we will do in the
discussion). Next, we assume that within-host populations have a probability, $t{\cdot}e$, per unit of time, to be
treated (*t*) and to evolve to become resistant (*e*). The treatment parameter *t* is the probability per unit time
that the host is treated and the evolution parameter *e* is the probability that the within-host pathogen
population evolves to become resistant through mutation or the acquisition of a genetic element, given that
the host is treated. Mathematically, $t{\cdot}e$ plays the role of the mutation parameter μ in the standard model
(see Table 1). Next, we assume that resistance comes with a mild fitness cost, *c*, which can be understood
as a reduction in R0 compared to the R0 of the susceptible pathogen strain. The fitness cost parameter, *c*,
determines how likely the resistant strain is to be transmitted compared to non-resistant strains (Wagner,
Garcia-Lerma, and Blower 2012). Mathematically, *c* plays the role of *s* (negative selection) in the standard
mutation-selection model (see Table 1). We refer to the fraction of hosts that is infected with a resistant
strain out of all infected hosts as *f*. Only susceptible strains (*1-f* of the pathogen population) can evolve to
become resistant.
Under this model, the frequency of resistant strains, *f*, will increase with $t{\cdot}e{\cdot}(1\text{-}f)$ per unit time
through positive selection within hosts and will be reduced by negative selection with $-c{\cdot}f{\cdot}(1\text{-}f)$. Thus the
change in frequency (f') can be written as:

$$f' \;=\; (t \cdot e)\,(1 - f) \;-\; c \cdot f(1 - f)\,.$$
An equilibrium will be reached when
$$(t \cdot e)\,(1 - f) \;=\; c \cdot f\,(1 - f)\;,$$
which means that the predicted equilibrium frequency of resistance will be:
$f \;=\; (t \cdot e)/(c)$, see **Figure 2**. This equilibrium result can explain the stability of the level of
resistance (f), the linear relationship between treatment levels (through t) and the level of resistance (f),
while allowing for evolution of new resistant strains to occur.
141

142
143
Figure 2: The level of resistance predicted by the Resistance Acquisition –
Purifying Selection (RAPS) model for a population of pathogens is a function of the probability of
resistance evolution per infection, $t \cdot e$, and the cost of resistance, c. *Higher levels of treatment lead to*
higher values of $t \cdot e$, consistent with Key Observation 2 about drug resistance. Strains acquire resistance
by mutation or through HGT. Resistant strains can be transmitted to other hosts, but with a lower rate of
transmission compared to susceptible strains. If time is measured per infection, then c is the difference
between the R0 for the susceptible strain and the resistant strain.

Table 1. Parameters for resistance acquisition-purifying selection (RAPS) model vs classical mutation-selection equilibrium model.

Model parameter	Mutation – selection balance		Resistance acquisition – negative selection balance	
Generation of new variants	μ	mutation per generation	$t \cdot e$	treatment and within-host evolution due to treatment per unit time
Selection against the variants	s	deleterious selection coefficient per generation	c	cost of drug resistance in the general population per unit time
Equilibrium frequency of the variant	$f = \frac{\mu}{s}$		$f = \frac{t \cdot e}{c}$	

Genomic and phenotypic data

Using 16 years of publicly available data for resistance to several drugs in *E. coli* in Norway (Gladstone et al. 2021), we show that resistance acquisition is common and that most resistant strains are short-lived, which is consistent with the RAPS model. We used a dataset of *E. coli* genomes from bloodstream infections in Norway consisting of 3254 isolates from a surveillance program from 2002 - 2017.

Using the phylogenetic tree and the phenotypic resistance data provided by the authors of the original paper (Gladstone et al. 2021), we estimated that ampicillin resistance evolved over 400 times on the tree, and resistance to the other drugs (cefotaxime, ciprofloxacin, gentamicin and piperacillin-tazobactam) evolved between 43 and 93 times (Figure 3B) [see Methods]. Note that the big difference in the number of evolutionary origins between ampicillin and the other drugs is consistent with the fact that ampicillin is an antibiotic that is much more often prescribed than the others (ECDC 2023).

We found that for the five drugs we looked at, at least 75% of the strains were observed in only one year in the dataset (Figure 3C). The lifespan of individual resistant strains was estimated by determining, for each origin of resistance, in which years the resulting resistant strain was observed in the dataset. We acknowledge that these lifespan estimates depend on the sampling density and are likely underestimates. Next, we created an area plot that shows how most ciprofloxacin (quinolone) resistant strains are only seen for a short time span, but that also shows a few longer-lived strains and one resistant strain that is long-lived and reaches a high frequency (3D). While the many strains that appear and disappear again are consistent with the RAPS model, the model cannot explain the behavior of the strain that increases in frequency over several years. In fact, it is unlikely that this increase is driven by the resistance to ciprofloxacin, instead, as others have suggested, it could be that by chance the ciprofloxacin resistance mutations landed on a background with positively selected elements and are hitchhiking to high frequency (Kallonen et al. 2017).

In summary, our analysis of the Norwegian dataset shows that resistant strains to five different drugs evolve often, yet, most resistant strains do not stay in the population for long, which is consistent with ongoing selection against resistance and with the RAPS model. Yet, there are a few long-lived resistance strains which are unexplained by the RAPS model and which account for a significant portion of resistance in *E. coli*.

Figure 3: Dynamics of drug-resistant strains in Norway. *a. Resistance trends in Norway for five drugs based on* (ECDC 2023; Gladstone et al. 2021). *b. Estimated number of origins of resistance to five drugs. c. Lifespans of resistant strains. d. Turnover of ciprofloxacin (quinolone) resistant strains*

Discussion

In order to understand, predict and influence levels of drug resistance in pathogens, we need mathematical models. Here we show that a simple model with strong positive selection for drug resistance within treated hosts and mild negative (purifying) selection in the rest of the population can explain three key observations about drug resistance in a variety of pathogens (**Figure 1**). First, the resistance acquisition – purifying selection (RAPS) model explains the stable coexistence of resistance and susceptibility in pathogen populations. Second, it explains the positive correlation between the amount of drugs used and the

frequency of drug resistance (**Figure 2**). And finally, it recapitulates the simultaneous existence of many different strains that carry a resistance mutation or genetic element at any one time (**Figure 1C**).

A major strength of the RAPS model is its simplicity. It relies on only a few assumptions and doesn't require consideration of co-infection or spatial structure of the host population. One benefit of this simplicity is that the model is more likely to be applicable to different pathogen systems. The most important assumption we make is that resistance comes with a fitness cost for the pathogen, reducing its R0 – if that is not the case, resistant strains will outcompete susceptible strains (Cohen and Murray 2004). A major difference between our model and some previous models that attempt to explain stable coexistence of drug resistance and susceptibility (Krieger et al. 2020; Colijn et al. 2009) is that the RAPS model includes the creation and dying out of resistant strains. This can happen even when the specific genetic elements that confer resistance are stably present in the population. One reason why researchers have often chosen to ignore the creation and dying out of resistant strains is because it is assumed that drug-resistant strains are stable. However, stability at the phenotypic level doesn't necessarily mean stability at the genetic level. New strains may evolve resistance in the same way as previous strains, even acquiring genetic elements from previous strains. The result is that the genetic element or the mutation may be stably present, but "who" carries it may always be changing (**Figure 3D**).

Another major strength of our model is that it makes clear and testable predictions. 1. It predicts that for a given drug, the higher levels of resistance in countries with high drug usage is due to the fact that resistance acquisition happens more often. We should therefore see more independently evolved resistant strains in countries with high levels of resistance. 2. The lifespan of resistant strains in a population should depend on the cost of the resistance for the pathogen. High-cost resistance should be associated with a shorter life span and, conversely, when resistance strains are generally short-lived this suggests that costs of resistance are high. 3. The time scale at which resistance levels change when treatment habits change should depend on the lifespans of resistant strains. Short life spans mean that a new equilibrium can be reached faster, and interventions should pay off more quickly. Intervention studies where ciprofloxacin (quinolone) use was reduced seem to indicate that this has an effect on resistance levels in a few months (Sarma et al. 2015; Gottesman et al. 2009).

Thanks to publicly available data, we were able to show that stability at the population level hides dynamic changes at lower levels (see **Figure 3A-D**). Although the resistance phenotype is present at a stable level (**Figure 3A**), resistance is due to many evolutionary origins (**Figure 3B**) and 75% of resistant strains are only present for a year (**Figure 3C-D**). It will be of interest to see if more granular data (e.g., monthly surveillance from a hospital) would show the waxing and waning of resistant strains. A major open question is why there are some long-lived resistance strains while most are so short-lived. Are these long-lived strains hitchhiking with other genetic elements as others have suggested (Kallonen et al. 2017)? Do these strains occasionally lose the resistant phenotype, as would be expected if the resistance is a costly hitchhiker?

It is of interest to see if what we know about treatment levels and drug resistance evolution probabilities roughly fits with the model. Because we don't know the typical time of an *E. coli* infection, we will use year as the unit of time here. We take the European data and estimate the slope of a linear model that goes through the origin (assuming no resistance if there is no treatment in a country), we find that the frequency of resistance goes up by about 10% for each 7% probability of treatment per year per person (assuming ciprofloxacin treatment is on average 5 days). Under the RAPS model, this means that the ratio between e (the evolution of resistance evolution) and c (the fitness cost per year of resistance) should be 0.1/0.07. If e is 10% (as suggested by Yaffe et al. (2023)) then c must be around 7%. If the fitness cost is

much higher (e.g., as suggested by the decrease in resistance from 12 to 9% in 6 months in Gottesman et
al. (2009)) then e must be much higher than 10%. Now, it should be clear that for each of these estimates
we have very little information. It is entirely possible that the Yaffe and Gottesman paper estimates are both
not correct. Clearly, we need more studies that estimate the probability of evolution of resistance (e) and
the cost of resistance in the real world (c). Having more such studies will make it possible to test whether
the RAPS model is correct or not and possibly which additional effects need to be taken into account for
future studies. For example, we are not including the introduction of resistant strains from farms, the
possibility that the cost of resistance is not the same everywhere or on every genetic background and
migration between countries.
Our study has several limitations. One limitation is that the model considers only resistance to a
single drug and not interactions between drugs or resistances. For example, when plasmids carry multiple
resistance genes, resistance to one drug can be acquired due to selection for resistance to another drug. We
also assumed that treatment does not affect transmission. If treatment itself is associated with strongly
reduced transmission (as is the case in HIV), then it would be useful if the model included the treatment
state of hosts, where the transmission probability of hosts on treatment is significantly lower than those not
on treatment (Kühnert et al. 2018; Stadler et al. 2013). The cost of resistance may also vary between strains
and may be affected by compensatory mutations (Cohen and Murray 2004; Hinz et al. 2023).
If stable levels of resistance mask the ongoing appearance of new resistant strains, this may have
implications for machine learning methods that are used to predict drug resistance phenotypes from
genomic data. At any given year and location, a machine learning algorithm may learn to recognize certain
strains responsible for much of the resistance burden in a species. Yet, over time, these resistant strains may
be replaced by others, which means that we likely need to re-train such models for current and local
situations (Moradigaravand et al. 2018).
In conclusion, we propose a simple model that explains why drug resistance can stably co-exist
with susceptible strains at levels that depend on drug usage. The model also explains why drug resistance
is often present in many different strains (phylogenetic clusters, genetic backgrounds or sequence types)
and predicts that resistant strains evolve and disappear again regularly. Data for resistance to several drugs
in *E. coli* in Norway are largely consistent with these predictions, though the model does not explain why
some resistant strains are seen over many years. This novel model has the potential to help us understand,
predict and influence drug resistance levels and because of its simplicity, it can be readily tested in many
different pathogen systems such as *S. pneumoniae* (Colijn et al. 2009; Krieger et al. 2020), *S. aureus*
(Diekema et al. 2019) and HIV (Rhee et al. 2019; Rocheleau et al. 2018)).

Acknowledgements

277 I am grateful for comments from and discussions with Kristin Harper, Joachim Hermisson, Sarah Cobey,
278 Alison Feder, Nandita Garud, Oana Carja, Rasmus Nielsen, Alison Hill, Scott Roy, Brandon Ogbunu, Ruth
279 Hershberg and the students in the SFSU CodeLab. Olivia Pham helped with figure 1.

Bibliography

Barton, Nicholas H., Derek E. G. Briggs, Jonathan A. Eisen, David B. Goldstein, and Nipam H. Patel.
2007. *Evolution*. First Edition. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press.
Baum, David A., Douglas J. Futuyma, Hopi E. Hoekstra, Richard E. Lenski, Allen J. Moore, Cahterine L.

Peichel, Dolph Schluter, and Michael C. Whitlock. 2017. *The Princeton Guide to Evolution*.
Princeton University Press.
Blanquart, François, Sonja Lehtinen, Marc Lipsitch, and Christophe Fraser. 2018. "The Evolution of
Antibiotic Resistance in a Structured Host Population." *Journal of The Royal Society Interface* 15
(143): 20180040. https://doi.org/10.1098/rsif.2018.0040.
Bollback, Jonathan P. 2006. "SIMMAP: Stochastic Character Mapping of Discrete Traits on
Phylogenies." *BMC Bioinformatics* 7 (1): 88. https://doi.org/10.1186/1471-2105-7-88.
Boni, Maciej F, Julia R Gog, Viggo Andreasen, and Marcus W Feldman. 2006. "Epidemic Dynamics and
Antigenic Evolution in a Single Season of Influenza A." *Proceedings of the Royal Society B:*
Biological Sciences 273 (1592): 1307–16. https://doi.org/10.1098/rspb.2006.3466.
Casali, Nicola, Vladyslav Nikolayevskyy, Yanina Balabanova, Simon R. Harris, Olga Ignatyeva, Irina
Kontsevaya, Jukka Corander, et al. 2014. "Evolution and Transmission of Drug-Resistant
Tuberculosis in a Russian Population." *Nature Genetics* 46 (3): 279–86.
https://doi.org/10.1038/ng.2878.
Chatzopoulou, M., and L. Reynolds. 2020. "Role of Antimicrobial Restrictions in Bacterial Resistance
Control: A Systematic Literature Review." *Journal of Hospital Infection* 104 (2): 125–36.
https://doi.org/10.1016/j.jhin.2019.09.011.
Cobey, Sarah, Edward B. Baskerville, Caroline Colijn, William Hanage, Christophe Fraser, and Marc
Lipsitch. 2017. "Host Population Structure and Treatment Frequency Maintain Balancing
Selection on Drug Resistance." *Journal of The Royal Society Interface* 14 (133): 20170295.
https://doi.org/10.1098/rsif.2017.0295.
Cohen, Ted, and Megan Murray. 2004. "Modeling Epidemics of Multidrug-Resistant M. Tuberculosis of
Heterogeneous Fitness." *Nature Medicine* 10 (10): 1117–21. https://doi.org/10.1038/nm1110.
Colijn, Caroline, Ted Cohen, Christophe Fraser, William Hanage, Edward Goldstein, Noga Givon-Lavi,
Ron Dagan, and Marc Lipsitch. 2009. "What Is the Mechanism for Persistent Coexistence of
Drug-Susceptible and Drug-Resistant Strains of Streptococcus Pneumoniae?" *Journal of The*
Royal Society Interface 7 (47): 905–19. https://doi.org/10.1098/rsif.2009.0400.
Davies, Nicholas G., Stefan Flasche, Mark Jit, and Katherine E. Atkins. 2019. "Within-Host Dynamics
Shape Antibiotic Resistance in Commensal Bacteria." *Nature Ecology & Evolution* 3 (3): 440–49.
https://doi.org/10.1038/s41559-018-0786-x.
Davies, Nicholas G, Stefan Flasche, Mark Jit, and Katherine E Atkins. 2021. "Modeling the Effect of
Vaccination on Selection for Antibiotic Resistance in Streptococcus Pneumonia E." *Science*
Translational Medicine 13 (606): eaaz8690.
Diekema, Daniel J, Michael A Pfaller, Dee Shortridge, Marcus Zervos, and Ronald N Jones. 2019.
"Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus Aureus From the
SENTRY Antimicrobial Surveillance Program." *Open Forum Infectious Diseases* 6 (Suppl 1):
S47–53. https://doi.org/10.1093/ofid/ofy270.
ECDC. 2018. "Antimicrobial Consumption - Annual Epidemiological Report for 2015." June 12, 2018.
https://www.ecdc.europa.eu/en/publications-data/antimicrobial-consumption-annual-
epidemiological-report-2015.
———. 2023. "Surveillance Atlas of Infectious Diseases." April 28, 2023.
https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases.
Gladstone, Rebecca A., Alan McNally, Anna K. Pöntinen, Gerry Tonkin-Hill, John A. Lees, Kusti
Skytén, François Cléon, et al. 2021. "Emergence and Dissemination of Antimicrobial Resistance
in Escherichia Coli Causing Bloodstream Infections in Norway in 2002–17: A Nationwide,
Longitudinal, Microbial Population Genomic Study." *The Lancet Microbe* 2 (7): e331–41.
https://doi.org/10.1016/S2666-5247(21)00031-8.
Goossens, Herman, Matus Ferech, Robert Vander Stichele, and Monique Elseviers. 2005. "Outpatient
Antibiotic Use in Europe and Association with Resistance: A Cross-National Database Study."
The Lancet 365 (9459): 579–87. https://doi.org/10.1016/S0140-6736(05)17907-0.
Gordo, Isabel, M. Gabriela M. Gomes, Daniel G. Reis, and Paulo R. A. Campos. 2009. "Genetic

Diversity in the SIR Model of Pathogen Evolution." *PLoS ONE* 4 (3): e4876.
https://doi.org/10.1371/journal.pone.0004876.

Gottesman, Bat Sheva, Yehuda Carmeli, Pnina Shitrit, and Michal Chowers. 2009. "Impact of Quinolone
Restriction on Resistance Patterns of Escherichia Coli Isolated from Urine by Culture in a
Community Setting." *Clinical Infectious Diseases* 49 (6): 869–75.
https://doi.org/10.1086/605530.

Hartl, Daniel L., and Russel B. Campbell. 1982. "Allele Multiplicity in Simple Mendelian Disorders."
American Journal of Human Genetics 34 (6): 866–73.

Hartl, Daniel L., and Andrew G. Clark. 2006. *Principles of Population Genetics*. Fourth Edition, Fourth
Edition. Oxford, New York: Oxford University Press.

Hinz, Aaron, Andre Amado, Rees Kassen, Claudia Bank, and Alex Wong. 2023. "Unpredictability of the
Fitness Effects of Antimicrobial Resistance Mutations across Environments in Escherichia Coli."
bioRxiv. https://doi.org/10.1101/2023.10.25.563906.

Huelsenbeck, John P., Rasmus Nielsen, and Jonathan P. Bollback. 2003. "Stochastic Mapping of
Morphological Characters." *Systematic Biology* 52 (2): 131–58.
https://doi.org/10.1080/10635150390192780.

Kallonen, Teemu, Hayley J. Brodrick, Simon R. Harris, Jukka Corander, Nicholas M. Brown, Veronique
Martin, Sharon J. Peacock, and Julian Parkhill. 2017. "Systematic Longitudinal Survey of
Invasive Escherichia Coli in England Demonstrates a Stable Population Structure Only
Transiently Disturbed by the Emergence of ST131." *Genome Research*, July.
https://doi.org/10.1101/gr.216606.116.

Kouyos, Roger, Eili Klein, and Bryan Grenfell. 2013. "Hospital-Community Interactions Foster
Coexistence between Methicillin-Resistant Strains of Staphylococcus Aureus." *PLOS Pathogens*
9 (2): e1003134. https://doi.org/10.1371/journal.ppat.1003134.

Krieger, Madison S., Carson E. Denison, Thayer L. Anderson, Martin A. Nowak, and Alison L. Hill.
2020. "Population Structure across Scales Facilitates Coexistence and Spatial Heterogeneity of
Antibiotic-Resistant Infections." *PLOS Computational Biology* 16 (7): e1008010.
https://doi.org/10.1371/journal.pcbi.1008010.

Kühnert, Denise, Roger Kouyos, George Shirreff, Jūlija Pečerska, Alexandra U. Scherrer, Jürg Böni,
Sabine Yerly, et al. 2018. "Quantifying the Fitness Cost of HIV-1 Drug Resistance Mutations
through Phylodynamics." *PLOS Pathogens* 14 (2): e1006895.
https://doi.org/10.1371/journal.ppat.1006895.

Moradigaravand, Danesh, Martin Palm, Anne Farewell, Ville Mustonen, Jonas Warringer, and Leopold
Parts. 2018. "Prediction of Antibiotic Resistance in Escherichia Coli from Large-Scale Pan-
Genome Data." *PLOS Computational Biology* 14 (12): e1006258.
https://doi.org/10.1371/journal.pcbi.1006258.

Murray, Christopher J. L., Kevin Shunji Ikuta, Fablina Sharara, Lucien Swetschinski, Gisela Robles
Aguilar, Authia Gray, Chieh Han, et al. 2022. "Global Burden of Bacterial Antimicrobial
Resistance in 2019: A Systematic Analysis." *The Lancet* 399 (10325): 629–55.
https://doi.org/10.1016/S0140-6736(21)02724-0.

Nouhuijs, Florentine van, MaryGracy Arakkal Antony, Faye Orcales, Landen Gozashti, Scott W. Roy, C.
Brandon Ogbunugafor, and Pleuni S. Pennings. 2022. "A Phylogenetic Approach to Studying the
Roles of Within-Host Evolution and between-Host Transmission of Resistance for Clinical
Escherichia Coli Infections." Preprint. Evolutionary Biology.
https://doi.org/10.1101/2022.12.16.520823.

Nubel, U., P. Roumagnac, M. Feldkamp, J.-H. Song, K. S. Ko, Y.-C. Huang, G. Coombs, et al. 2008.
"Frequent Emergence and Limited Geographic Dispersal of Methicillin-Resistant Staphylococcus
Aureus." *Proceedings of the National Academy of Sciences* 105 (37): 14130–35.
https://doi.org/10.1073/pnas.0804178105.

Nübel, Ulrich, Philippe Roumagnac, Mirjam Feldkamp, Jae-Hoon Song, Kwan Soo Ko, Yhu-Chering
Huang, Geoffrey Coombs, et al. 2008. "Frequent Emergence and Limited Geographic Dispersal

of Methicillin-Resistant Staphylococcus Aureus." *Proceedings of the National Academy of*
Sciences 105 (37): 14130–35. https://doi.org/10.1073/pnas.0804178105.

Revell, Liam J. 2012. "Phytools: An R Package for Phylogenetic Comparative Biology (and Other
Things): *Phytools: R Package*." *Methods in Ecology and Evolution* 3 (2): 217–23.
https://doi.org/10.1111/j.2041-210X.2011.00169.x.

Rhee, Soo-Yon, Dana Clutter, W Jeffrey Fessel, Daniel Klein, Sally Slome, Benjamin A Pinsky, Julia L
Marcus, et al. 2019. "Trends in the Molecular Epidemiology and Genetic Mechanisms of
Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic
Population." *Clinical Infectious Diseases* 68 (2): 213–21. https://doi.org/10.1093/cid/ciy453.

Rocheleau, G., C. J. Brumme, J. Shoveller, V. D. Lima, and P. R. Harrigan. 2018. "Longitudinal Trends
of HIV Drug Resistance in a Large Canadian Cohort, 1996–2016." *Clinical Microbiology and*
Infection 24 (2): 185–91. https://doi.org/10.1016/j.cmi.2017.06.014.

Rodrigues, Paula, M. Gabriela M. Gomes, and Carlota Rebelo. 2007. "Drug Resistance in Tuberculosis—
a Reinfection Model." *Theoretical Population Biology* 71 (2): 196–212.
https://doi.org/10.1016/j.tpb.2006.10.004.

Sarma, J. B., B. Marshall, V. Cleeve, D. Tate, T. Oswald, and S. Woolfrey. 2015. "Effects of
Fluoroquinolone Restriction (from 2007 to 2012) on Resistance in Enterobacteriaceae:
Interrupted Time-Series Analysis." *Journal of Hospital Infection* 91 (1): 68–73.
https://doi.org/10.1016/j.jhin.2015.05.006.

Schuts, Emelie C, Anders Boyd, Anouk E Muller, Johan W Mouton, and Jan M Prins. 2021. "The Effect
of Antibiotic Restriction Programs on Prevalence of Antimicrobial Resistance: A Systematic
Review and Meta-Analysis." *Open Forum Infectious Diseases* 8 (4): ofab070.
https://doi.org/10.1093/ofid/ofab070.

Shin, Juyoun, Myung-Jin Choi, and Kwan Soo Ko. 2012. "Replicon Sequence Typing of IncF Plasmids
and the Genetic Environments of blaCTX-M-15 Indicate Multiple Acquisitions of blaCTX-M-15
in Escherichia Coli and Klebsiella Pneumoniae Isolates from South Korea." *Journal of*
Antimicrobial Chemotherapy 67 (8): 1853–57. https://doi.org/10.1093/jac/dks143.

Stadler, Tanja, Denise Kühnert, Sebastian Bonhoeffer, and Alexei J. Drummond. 2013. "Birth–Death
Skyline Plot Reveals Temporal Changes of Epidemic Spread in HIV and Hepatitis C Virus
(HCV)." *Proceedings of the National Academy of Sciences* 110 (1): 228–33.
https://doi.org/10.1073/pnas.1207965110.

Wagner, Bradley G., J. Gerardo Garcia-Lerma, and Sally Blower. 2012. "Factors Limiting the
Transmission of HIV Mutations Conferring Drug Resistance: Fitness Costs and Genetic
Bottlenecks." *Scientific Reports* 2 (1): 320. https://doi.org/10.1038/srep00320.

Wakeley, John. 2008. "Conditional Gene Genealogies under Strong Purifying Selection." *Molecular*
Biology and Evolution 25 (12): 2615–26. https://doi.org/10.1093/molbev/msn209.

Yaffe, Eitan, Les Dethlefsen, Arati V. Patankar, Chen Gui, Susan Holmes, and David A. Relman. 2023.
"A Short Course of Antibiotics Selects for Persistent Resistance in the Human Gut." bioRxiv.
https://doi.org/10.1101/2023.09.04.556257.

Methods

427 All code and data are available on github https://github.com/pleunipennings/CoexistencePaper.

428 Figure 1A European surveillance data

429 Quinolone resistance over time in 10 European countries.

430 Data were downloaded from the European Surveillance Atlas for Infectious Diseases.

431 Link https://atlas.ecdc.europa.eu/public/index.aspx .

As health topic, we chose "Antimicrobial resistance", as subpopulation "*Escherichia coli/*" and "fluoroquinolones" and as indicator "percentage resistance". We then downloaded a csv file with data for all available years and regions (named ECDC_surveillance_data_Antimicrobial_resistance_complete_DownloadApril2024.csv in the Github repository). For Figure 1A we included the 10 most populous countries in the EU, including the United Kingdom: Germany, United Kingdom, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic (ECDC 2023).

Figure 1B European surveillance data

For figure 1B, we used the percentage fluoroquinolone resistance in 2015 from the dataset described for Figure 1A, but now for the 20 most populous countries. This included in addition to the first 10: Sweden, Portugal, Greece, Hungary, Austria, Bulgaria, Denmark, Finland, Slovakia, Ireland.
For data on the use of fluoroquinolones in these countries, we downloaded data from https://www.ecdc.europa.eu/en/publications-data/antimicrobial-consumption-annual-epidemiological-report-2015 which included "Downloadable tables: Antimicrobial consumption - Annual Epidemiological Report for 2015" (ECDC 2018).

Figure 1C *E. coli* phylogenetic tree Kallonen dataset from Nouhuijs et al.

The phylogenetic tree in Figure 1C was reproduced from (van Nouhuijs et al. 2022). Data presented here include only *E. coli* strains from phylogroup D and F. The genomes and phenotypes were described in (Kallonen et al. 2017). Briefly, a core genome alignment was used to create a phylogenetic tree, then we simulated a single history of the resistance phenotype using the "simmap" function in Phytools (Bollback 2006; Revell 2012), the simulated history is shown on the tree with resistant branches in red, susceptible branches in green and intermediate branches in green.

Figure 3A Resistance trends in Norway for five drugs

Data are from Gladstone, 2021 (Gladstone et al. 2021) and from the ECDC Surveillance Atlas (ECDC 2023).

Figure 3B Estimated number of origins of resistance to five drugs

We used the tree and metadata provided by Gladstone, 2021 (Gladstone et al. 2021). Intermediate and susceptible strains were lumped in one category. We simulated a single history of the resistance phenotype using the "simmap" stochastic character mapping function in Phytools (Revell 2012) which is based on methods by (Bollback 2006; Huelsenbeck, Nielsen, and Bollback 2003). Next, we used a custom R script to identify the last resistant ancestor for each resistant tip of the tree. If two tips share a last resistant ancestor, we assume that they are resistant due to the same evolutionary origin of resistance. This evolutionary origin may be due to a mutation, several mutations or horizontal gene transfer – our approach is based on the phenotypes, not the genotypes. Based on the simmap results, we count the number of times resistance was acquired on the tree.

468
469 Supplementary figure 1. In this example, there are three resistant tips. The branches are colored according
470 to the simmap stochastic character mapping. R1 and R2 share a last resistant ancestor and are therefore
471 assumed to be resistant due to the same evolutionary event in their history, we consider them part of the
472 same resistant cluster or resistant strain. For R3, the last resistant ancestor is itself. It is the only member of
473 the resistant cluster or strain.

Figure 3C Lifespans of resistant strains

475 Using the results from analysis described for 3B and the metadata from (Gladstone et al. 2021) to determine
476 for each inferred resistance cluster for how many years it was observed in the data. For example, if R1 was
477 a sample from 2005 and R2 was a sample from 2007, then we infer that the lifespan of this cluster was 3
478 years.

Figure 3D Turnover of ciprofloxacin (quinolone) resistant strains

480 Using the results from analysis described for 3B and the metadata from (Gladstone et al. 2021) to determine
481 for each inferred ciprofloxacin resistance cluster what its frequency was in each year.